

## Drug and Therapeutics Committee – Minutes – Confirmed

<b>Date / Time</b>	Thursday 14th June 2018 8:15am – 9:30am
<b>Venue</b>	The Board Room, Alderson House, HRI
<b>Chair</b>	Prof A Morice, Chair, Professor of Respiratory Medicine
<b>Notes / Action Points</b>	Mrs W Hornsby, Senior Pharmacy Technician
<b>Quorate: Yes / No</b>	Yes

<b>Attendance</b>	Mr S Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services (SG) Mr P O'Brien, Deputy Chief Pharmacist Dr F Umerah, Consultant Anaesthetist Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Prof M Lind, Vice Chair, Professor of Oncology Dr A Samson, Infectious Diseases Consultant Dr S Raise, GP ER CCG (via speakerphone)
-------------------	--

<b>Apologies</b>	Dr O Ogunbambi, Consultant Rheumatologist Mr K McCorry, Medicines Optimisation Pharmacist, East Riding CCG Dr H Klonin, Consultant Paediatrician Mr R Kapur, Vascular Surgeon
------------------	--

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2018.06.01	<b>Apologies</b>	As above.					
2018.06.02	<b>Declarations of Interest</b>	None.					06/18
2018.06.03	<b>Minutes of the previous meeting</b>	<p>The minutes were accepted as a true record with the following amendments:  Page 4 to be altered to read  FU had discussed aprotinin with the clinical director for anaesthetics who has not expressed interested in its use  FU agreed to send copy of surgery minutes to POB/SG/AM to confirm this</p> <p>Formulary to be altered to include the following  Aprotinin – NOT APPROVED</p>	<p>Minutes to be altered</p> <p>Confirm decision with surgery</p> <p>WH to amend formulary</p>	<p>WH to alter minutes</p> <p>AM to write to cardiothoracic surgery to confirm they are happy with this course of action</p>	<p>WH</p> <p>AM</p> <p>WH</p>	<p>7/18</p> <p>7/18</p> <p>7/18</p>	
2018.06.04	<b>Action Tracker</b>	<p>D&amp;T Attendance  SG has emailed lay member twice but had no response.  New action- DC to discuss lay member appointment with Louise Beedle</p> <p>D&amp;T Product Requests  NICE TA's have now been highlighted on spreadsheet</p> <p>NICE Guidance  POB informed the group that Oncology have drafted a new process for D&amp;T submissions which will be discussed at the next Chemo Committee meeting and presented at D&amp;T in July</p> <p>NICE Guidance  WH has prepared a list of all oncology products which have not</p>	<p>DC will discuss lay member with Louise Beedle</p> <p>Action complete</p> <p>WH to invite SS to next D&amp;T meeting in July</p> <p>POB will need to</p>		<p>DC</p> <p>WH</p> <p>WH</p> <p>POB</p>	<p>7/18</p> <p>7/18</p> <p>7/18</p>	6/18

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>submitted a new product request to D&amp;T and are therefore not on formulary. POB will discuss list with oncology to ensure all relevant services are available at HEY</p> <p>Fendix Media Advertising Campaign on Pattie Ongoing feedback in August</p> <p>Tracker POB has forwarded aprotinin details to FU and AM</p> <p>NICE Guidance TA517 Avelumab new product request will now be submitted in August once new process in place</p> <p>DSU Valproate Warnings- have now been discussed at HERPC and MMIG</p> <p>DSU AM has written to Dr Abouda regarding risk of serious liver injury when using Obeticholic acid</p> <p>St Marks solution has been added to unlicensed list</p>	<p>check which drugs will be needed at HEY and feedback</p> <p>Ongoing</p> <p>Action complete</p> <p>Remove from tracker</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>		<p>DC</p> <p>POB</p> <p>ML</p> <p>WH</p> <p>AM</p> <p>WH</p>	<p>8/18</p> <p></p> <p></p> <p></p> <p></p> <p></p>	<p></p> <p>6/18</p> <p>6/18</p> <p>6/18</p> <p>6/18</p> <p>6/18</p>
2018.06.05	<b>New Product Requests</b>	<p>Flunarizine – Migraine – Dr Ahmed The product is not licensed in the UK for this condition but currently HEY are referring patients to London for treatment. NICE evidence summary ESUOM33 states consider treatment with Flunarizine but cannot recommend as not licensed. It was agreed to approve for use by headache team only and to ensure patients are consented. Headache comes under block contract with CCG and as cost is small this should not impact on CCG</p> <p>Plenvu – Bowel Cleansing – Mark Hughes Submission by nurse practitioner would like to use in 200 patients as part of audit. Product requires less fluid intake which is thought will aid patient compliance and experience. SR raised the issue that GPs receive queries from patients on how to use bowel cleansing preps which is an issue as clinic letters do not usually state which prep has been provided. It was thought</p>	<p>Approved</p> <p>Approved</p>	<p>AM to write to applicants WH to add to formulary</p>	<p>AM/ WH</p> <p>SG</p>	<p>7/18</p> <p>7/18</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		service would be better if preps could be provided in clinic with leaflet rather than posting prep to patient					
2018.06.06	<b>NICE Guidance</b>	<p>NG 89 Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Referred from MMIG due to recommendation of Aspirin as a treatment option Document replaces CG92 and makes several recommendations which are not currently HEY policy. Thrombosis committee agreed to discuss with representatives from relevant areas.</p> <p>SR asked if it would be possible to attend Thrombosis Committee</p> <p>May 18 TA 520 Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy</p>	<p>Noted</p> <p>SG to invite SR to attend Thrombosis committee</p> <p>NPR will come under new process</p>		SG	7/18	6/18
2018.06.07	<b>MHRA Drug Safety Update</b>	<p>Valproate – Pregnancy Prevention programme materials now on line Braltus – risk of inhalation of capsule if placed in mouthpiece</p>	Noted				6/18
2018.06.08	<b>Minutes from SMPC</b>	<p>SMPC Minutes 4<sup>th</sup> April Issues discussed: Injecting medicines policy requires input from anaesthetics Multidose vials Insulin on wards Issues on Lorenzo CQC report issues Annual CD assurance report Medusa has now gone live and all paper versions of the injectable guides have been removed from wards.</p> <p>ML asked for an update on E-prescribing DC said overall the process had been quite positive and was now live on 5 wards at QCOH and would be rolled out to Wd 7 CHH next week.</p>	Noted	No further action			6/18
2018.06.09	<b>Minutes from</b>	Bisphosphonates Guideline – ML informed the committee that Dr O'Neill is working with AR to finalise document	Noted	No further action			6/18

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
	<b>HERPC –April 2018</b>	Diabetes guideline approved New Vitamin D paper is being written					
2018.06.10	<b>Correspondence received</b>	KMc had emailed requesting Plenvu be made Red. POB confirmed that Plenvu would be given as part of the colonoscopy procedure and there would be no change to current costs.  KMc had also requested a discussion around Tinzaparin/Dalteparin switch. The switch could result in a possible saving to the trust of £100k Leo had agreed to provide a rebate to the CCGs to cover any losses incurred. The use of DOACS as an alternative to LMWH was discussed and it was agreed to update paper written in 2015 to include DOACS and then circulate paper at MMIG/HERPC/D&T/SMPC	Noted  SG to ask AR to update paper		SG	7/18	6/18
2018.06.11	<b>Chairs approvals</b>	Sunitib – Alveolar Soft Part Sarcoma – Dr G Bozas  Synvisc – Mr R Raman Agreed to add to formulary as “Hylan G-F 20 (Synvisc®) – for patients with CCG IFR funding approval only”	Approved  Approved				6/18  6/18
2018.06.12	<b>Issues to escalate to OQC</b>	None					6/18
2018.06.13	<b>Any Other Business</b>	SR ask if he would need access to PATTIE but was informed this was a trust employee only intranet  Orkambi – POB had received a request for the compassionate use of Orkambi in a child from Dr Barraclough via FOC scheme.  POB informed the committee a new product request was expected next month for triple HEP C therapy	Noted	No further action			6/18
2018.06.14	<b>Date and Time of Next Meeting</b>	Thursday 12 <sup>th</sup> July 8.15 – 9.30am , Trust Boardroom, HRI.					